Trial Profile

informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 01 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibrutinib (Primary) ; Bendamustine; Chlorambucil; Cyclophosphamide; Fludarabine; Obinutuzumab; Rituximab
Indications Chronic lymphocytic leukaemia
Focus Therapeutic Use
Acronyms informCLL

13 Dec 2022 Final Analysis Results from the InformCLL Registry assessing real-world (RW) outcomes in pts with CLL/SLL receiving first-line (1L) therapy, including comparison of 1L Ibr versus CIT presented at the 64th American Society of Hematology Annual Meeting and Exposition
10 Dec 2022 According to an AbbVie media release, data from the registry will be presented at the the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.
07 Jun 2022 Results evaluating treatment patterns and prognostic biomarker testing in Black patients, presented at the 58th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com